![[fetch_key]](https://stocktradeupdates.com/wp-content/uploads/new_logos/STAR.png)
Share the post "Strides Pharma Science ‘s Q3 2024-25 Latest News: Revenue Rises by 5.94% YoY"
Highlights
🔹 The presented financial data is Standalone to provide a comprehensive overview of the company performance. 🔹 Sales over the Year and quarter: The company experienced a substantial growth of 5.94 % in the past year, decrease in net sales/revenue by -9.68 %. 🔹 Income over the Year and quarter: There has been decline in other income over the past year which is -28.98 %, Marginal decrease of -89.76% in other income during this quarter. 🔹 Profit over the Year and quarter: Significant improvement in profitability for Strides Pharma Science Limited. Notable increase of 487.65 % in net profit Year to Year, Strides Pharma Science Limited’s profitability dropped by -2.42 % Quarter to Quarter. 🔹 EPS over the Year and quarter: EPS increased by 478.57 % Year to Year. EPS decreased by -2.41 % in previous quarter. Analysis needed for shareholder value.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 520.015 Cr | Rs. 609.957 Cr | Rs. 550.917 Cr | -9.68 % | + 5.94 % |
| Expenses | Rs. 454.36 Cr | Rs. 546.93 Cr | Rs. 476.82 Cr | -12.82 % | + 4.94 % |
| Operating Profit | Rs. 65.66 Cr | Rs. 63.03 Cr | Rs. 74.1 Cr | + 17.56 % | + 12.85 % |
| OPM % | 12.63 % | 10.33 % | 13.45 % | + 3.12 % | + 0.82 % |
| Other Income | Rs. 3.395 Cr | Rs. 23.537 Cr | Rs. 2.411 Cr | -89.76 % | -28.98 % |
| Interest | Rs. 44.47 Cr | Rs. 50.15 Cr | Rs. 34.21 Cr | -31.78 % | -23.07 % |
| Depreciation | Rs. 21.06 Cr | Rs. 21.98 Cr | Rs. 20.92 Cr | -4.82 % | -0.66 % |
| Profit before tax | Rs. 3.52 Cr | Rs. 14.44 Cr | Rs. 21.38 Cr | + 48.06 % | + 507.39 % |
| Tax % | 27.78 % | 6.07 % | 30.12 % | + 24.05 % | + 2.34 % |
| Net Profit | Rs. 2.54 Cr | Rs. 15.31 Cr | Rs. 14.94 Cr | -2.42 % | + 488.19 % |
| EPS in Rs | Rs. 0.28 | Rs. 1.66 | Rs. 1.62 | -2.41 % | + 478.57 % |
Today, we’re looking at Strides Pharma Science Limited’s financial performance for the Q3(Dec 2024-25).Starting with the top line, the company reported a robust year-over-year sales growth of 5.94 %. However, it did see a marginal slip of -9.68 % from the previous quarter. Expenses decreased slightly by -12.82 % quarter-on-quarter, aligning with the annual rise of 4.94 %. Operating profit, while up 12.85 % compared to last year, faced a quarter-on-quarter increase of 17.56 %, signaling a short-term expansion in margins.
The Operating Profit Margin (OPM) % echoes this narrative, showing resilience on an annual basis with an increase of 0.82 %, but an expansion of 3.12 % sequentially. Other income fell by -89.76 % compared to the last quarter, despite an annual decline of -28.98 %. Interest expenses dropped significantly by -31.78 % from the previous quarter, yet the year-over-year decrease remains at a moderate -23.07 %. Depreciation costs fell by -4.82 % quarter-on-quarter, yet on an annual scale, they experienced a reduction of -0.66 %. Profit before tax grew annually by 507.39 % but saw an increase from the preceding quarter by 48.06 %.
Tax expenses as a percentage of profits increased slightly by 2.34 % compared to last year, with a more notable quarter-on-quarter increase of 24.05 %. Net profit rose by 488.19 % year-on-year but witnessed a -2.42 % contraction from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual uptick of 478.57 % but a quarterly fall of -2.41 %. In summary, Strides Pharma Science Limited’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 520.015 Cr | Rs. 609.957 Cr | Rs. 550.917 Cr | -9.68 % | + 5.94 % |
| Expenses | Rs. 454.36 Cr | Rs. 546.93 Cr | Rs. 476.82 Cr | -12.82 % | + 4.94 % |
| Operating Profit | Rs. 65.66 Cr | Rs. 63.03 Cr | Rs. 74.1 Cr | + 17.56 % | + 12.85 % |
| Net Profit | Rs. 2.54 Cr | Rs. 15.31 Cr | Rs. 14.94 Cr | -2.42 % | + 488.19 % |
| EPS in Rs | Rs. 0.28 | Rs. 1.66 | Rs. 1.62 | -2.41 % | + 478.57 % |
In reviewing Strides Pharma Science Limited’s 2024-25(Q3) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales saw a robust 5.94 % year-on-year growth, although there was a slight dip of -9.68 % from the previous quarter. Expenses rose by 4.94 % compared to the previous year, with a decrease of -12.82 % quarter-on-quarter. Operating Profit surged by 12.85 % annually, and saw a 17.56 % increase from the last quarter.
Net Profit showed yearly increase of 488.19 %, and experienced a -2.42 % decrease from the previous quarter. Earnings Per Share (EPS) rose by 478.57 % annually, however dipped by -2.41 % compared to the last quarter. In essence, while Strides Pharma Science Limited exhibits strong annual growth indicators, short-term improvements suggest the potential for recovery and the importance of strategic adjustments to counter market challenges effectively. That’s all for now in the financial sector.
![[fetch_key]](https://stocktradeupdates.com/wp-content/uploads/new_logos/KARMAENG.png)
